| scholarly article | Q13442814 |
| P2093 | author name string | Michael Charlton | |
| Deborah Rasmussen | |||
| Raghavakaimal Sreekumar | |||
| Barbara Rosado | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | steatohepatitis | Q2335423 |
| P304 | page(s) | 244-251 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis | |
| P478 | volume | 38 |
| Q33947195 | A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits |
| Q52758998 | A liver-specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis |
| Q46413321 | A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. |
| Q36826832 | Activation of the Aryl Hydrocarbon Receptor Sensitizes Mice to Nonalcoholic Steatohepatitis by Deactivating Mitochondrial Sirtuin Deacetylase Sirt3 |
| Q33321721 | Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis |
| Q37621344 | An Intimate Relationship between ROS and Insulin Signalling: Implications for Antioxidant Treatment of Fatty Liver Disease |
| Q62067019 | Bioinformatics as tool to identify gene/protein-pathways associated with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis |
| Q30959523 | Combination of 'omics' data to investigate the mechanism(s) of hydrazine-induced hepatotoxicity in rats and to identify potential biomarkers |
| Q34317685 | Complement alternative pathway activation in human nonalcoholic steatohepatitis |
| Q53293047 | Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression? |
| Q43238371 | Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice |
| Q28507402 | Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice |
| Q47680877 | Differential carbonylation of proteins in end-stage human fatty and nonfatty NASH. |
| Q33222514 | Differential gene expression profiles in stage I primary biliary cirrhosis |
| Q80821815 | Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver |
| Q46848211 | Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray |
| Q42033362 | Extracellular matrix and cytochrome P450 gene expression can distinguish steatohepatitis from steatosis in mice. |
| Q35562084 | Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition |
| Q81480459 | Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease |
| Q46953374 | Gene expression profiling in livers of mice after acute inhibition of beta-oxidation. |
| Q37150528 | Genes and nonalcoholic fatty liver disease |
| Q46455710 | Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice |
| Q46515459 | Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis |
| Q45308989 | Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease |
| Q36839533 | Hepatitis C and insulin resistance: mutual interactions. A review |
| Q39377977 | Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance |
| Q36303106 | High Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery |
| Q34160734 | Identification of liver proteins altered by type 2 diabetes mellitus in obese subjects |
| Q35597601 | Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis |
| Q36322032 | In silico search for modifier genes associated with pancreatic and liver disease in Cystic Fibrosis |
| Q46702703 | Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease |
| Q36265230 | Is liver disease a threat to patients with metabolic disorders? |
| Q34003358 | Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease |
| Q42846205 | Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease |
| Q24629354 | MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism |
| Q34974769 | Microarray Evidences the Role of Pathologic Adipose Tissue in Insulin Resistance and Their Clinical Implications |
| Q40122130 | Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes |
| Q36338671 | Microarray technology in the study of obesity and non-alcoholic fatty liver disease |
| Q36013207 | Microarrays, antiobesity and the liver |
| Q37815476 | Mitochondria and redox signaling in steatohepatitis |
| Q37863137 | Mitochondrial dysfunction in nonalcoholic steatohepatitis |
| Q57807657 | Molecular pathways of nonalcoholic fatty liver disease development and progression |
| Q30375036 | Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. |
| Q38360416 | Non-Alcoholic Fatty Liver Disease: Current Perspectives and Future Direction in Disease pathogenesis, Treatment and Diagnosis |
| Q34285124 | Non-alcoholic fatty liver disease: an emerging pathological spectrum |
| Q35996525 | Nonalcoholic fatty liver disease: a review of current understanding and future impact |
| Q36744614 | Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). |
| Q30432576 | Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future |
| Q39165020 | Nrf2 Activators Attenuate the Progression of Nonalcoholic Steatohepatitis–Related Fibrosis in a Dietary Rat Model |
| Q36083434 | Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease |
| Q35064319 | Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome |
| Q42995609 | Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver |
| Q36179902 | Pathogenesis and management issues for non-alcoholic fatty liver disease |
| Q36814311 | Pathology of fatty liver disease |
| Q37195612 | Prosteatotic and Protective Components in a Unique Model of Fatty Liver: Gut Microbiota and Suppressed Complement System |
| Q42244880 | Protective effect of the Y220C mutant p53 against steatosis: good news? |
| Q79906046 | Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients |
| Q28192695 | Review article: the metabolic syndrome and non-alcoholic fatty liver disease |
| Q38687132 | Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity |
| Q37953770 | Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis |
| Q36814812 | Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease - A historical prospective |
| Q35989063 | Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats |
| Q37850490 | Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. |
| Q46397581 | Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease |
| Q36642598 | The Ups and Downs of Insulin Resistance and Type 2 Diabetes: Lessons from Genomic Analyses in Humans |
| Q57415496 | The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study) |
| Q36647336 | The hepatic transcriptome in human liver disease |
| Q37480831 | The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? |
| Q35821156 | The ins and outs of mitochondrial dysfunction in NASH. |
| Q37868177 | The role of oxidative stress in non-alcoholic steatohepatitis |
| Q38107674 | The role of the complement system in metabolic organs and metabolic diseases |
| Q58122029 | Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms |
| Q38638081 | Weight loss enhances hepatic antioxidant status in a NAFLD model induced by high fat diet |
Search more.